RxDoctor Payments Data

Ramona Andrei, MD

Obstetrics · Detroit, MINPI 1093916082

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.1% of the total across 50 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $206 and has fallen 61.3% since, to $80 in 2025. That places this record below the midpoint for obstetrics clinicians in MI, where the typical reported total is $841.

$875in general payments, 2019–2025

Across 50 payments — averaging $17.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$174
  • Pfizer$139
  • Aspira Women's Health Inc$84
  • Sumitomo Pharma America, Inc.$79
  • Johnson & Johnson$66
  • Astellas Pharma US Inc$52
  • plus $281 from 12 others

What the payments were for

  • Food & beverage$85898%
  • Education$172%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$875 in reported general payments places this provider in the 50th percentile of 48 obstetrics providers in Michigan.

See all obstetrics providers in Michigan

Medicare billing

Part B allowed, 2024
$50,684
Medicare patients
127
Services billed
347

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron19$16,248
PremarinEstrogens, Conjugated28$12,792
Estradiol169$6,173
Megestrol Acetate60$2,089
Oxybutynin Chloride ErOxybutynin Chloride78$1,886
Medroxyprogesterone Acetate114$1,827
Metronidazole78$1,349
Clobetasol Propionate61$1,267
Fluconazole112$781
Terconazole21$672
Halobetasol Propionate13$299
Raloxifene Hcl11$220
Venlafaxine Hcl ErVenlafaxine Hcl14$218
Ketoconazole19$201
ElinestNorgestrel-Ethinyl Estradiol23$194

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$52$16,24819 claims
PfizerPremarin$139$12,79228 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 48 obstetrics providers in Michigan.

Other obstetrics in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →